Fabry Disease clinical trials at UC Health
3 in progress, 1 open to new patients

  • Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function

    open to eligible people ages 18-60

    This is a randomized, double blind, active control study of PRX-102 (pegunigalsidase alfa) in Fabry disease patients with impaired renal function. Patients treated for approximately 1 year with agalsidase beta and on a stable dose for at least 6 months will be screened and then randomized to continue treatment with 1mg/kg agalsidase beta or to treatment with 1 mg/kg of PRX-102. The identity of the enzyme will be blinded to the patient and the investigator. Patients will receive intravenous infusions every two weeks. Patients will be randomized in a 2:1 ratio of PRX-102 to agalsidase beta. Randomization will be stratified by urinary protein to creatinine ratio (UPCR) of < or ≥ 1 g/g by spot urine sample. No more than 50% of the patients will be female.

    at UCLAUC IrvineUC DavisUCSD

  • Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease

    Sorry, not currently recruiting here

    This study aimed to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease.

    at UC Irvine

  • Extension Study of 1 mg/mL Pegunigalsidase Alfa in Patients With Fabry Disease

    Sorry, not yet accepting patients

    The objective of PB-102-F60 is to evaluate the long-term safety, tolerability, and efficacy parameters of 1 mg/kg pegunigalsidase alfa administered intravenously every other week in adult Fabry patients who have successfully completed studies PB-102-F20 or PB-102-F30.

    at UC Irvine

© The Regents of the University of California